Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.29
- Piotroski Score 2.00
- Grade Overweight
- Symbol (MXCT)
- Company MaxCyte, Inc.
- Price $3.23
- Changes Percentage (-5.56%)
- Change -$0.19
- Day Low $3.22
- Day High $3.45
- Year High $5.55
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.35
- Trailing P/E Ratio -13.89
- Forward P/E Ratio -13.89
- P/E Growth -13.89
- Net Income $-37,923,000
Income Statement
Quarterly
Annual
Latest News of MXCT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...
Maher Masoud discussed inventory write-down due to product redesign and new engineering head hired for efficient development. Vertex focuses on high-impact workflows and revenue to avoid future losses...
By Yahoo! Finance | 1 week ago -
Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT)
Maher Masoud, CEO of MaxCyte Inc, bought 100,000 shares at $4.89, investing $489,000. With a total of 200,000 shares, he has shown confidence in the company's cell engineering technologies....
By Yahoo! Finance | 5 months ago
